Idinvest Partners and Kurma Partners sell Prosensa to BioMarin for up to USD840m
BioMarin and Prosensa have reached an agreement whereby BioMarin will offer to purchase all of Prosensa’s outstanding ordinary shares, at USD17.75 per share, for a total consideration of approximately USD680 million. In addition, two approximately USD80 million contingent milestones are payable for the approval of drisapersen in the US no



